Cardiovascular risk consistent, not elevated across inflammatory bowel disease therapies

The risk for major adverse cardiovascular events appeared similar between older patients treated with 5-aminosalicylic acid and those who received immunomodulators or biologics for inflammatory bowel disease, data show.“Our findings are reassuring in that immunomodulators and biologics were not associated with elevated cardiovascular risk,” Tianze Jiao, PhD, assistant professor in the